

SUBJECT INDEX TO VOLUME 2

- Adolescent alcohol abuse dependence 159
 assessment methods of 162
 aversion therapy of 169
 behavioral/cognitive-behavioral interventions
 in 167
 comorbid psychiatric disorders in 164
 course of 163
 development considerations in psychosocial
 treatment of 166
 development of 159,160
 diagnosis of 159,161
 epidemiology of 159
 family-based interventions in 167
 health problems in 164
 motivational enhancement in 167
 pharmacological treatment of 169
 progression of 160
 psychosocial problems in 163
 sexual behavior in 164
 suicidal/homicidal behavior in 164
 treatment of 159,165
- Alcohol dependence 159
 assessment methods of 162
 aversion therapy of 169
 behavioral/cognitive-behavioral interventions
 in 167
 comorbid psychiatric disorders in 164
 course of 163
 development considerations in psychosocial
 treatment of 166
 development of 159,160
 diagnosis of 159,161
 epidemiology of 159
 family-based interventions in 167
 health problems in 164
 motivational enhancement in 167
 progression of 160
 psychosocial problems in 163
 sexual behavior in 164
 suicidal/homicidal behavior 164
 treatment of 159,165,169
- Alcohol withdrawn 169
 treatment of 169
- Alzheimer's disease (AD) 179
 alzhemedTM for 184
 amyloid hypothesis of 181
 anti-A β aggregation agents for 184
 clioquinol for 184
 colostrinin for 184
 disease modifying therapies for 179
 economic implications of disease modifying
 treatments in 179
 flurizanTM for 183
 HCT-1026 for 185
 immunotherapy for 182
 LY450139 for 183
 non-steroidal anti-inflammatory drugs
 (NSAIDs) for 184
 phenserine for 184
 secretase inhibitors for 182
 β -secretase inhibitors for 183
 selective A β 42-lowering agents for 183
 statins for 184
 treatments for 179
- Antidepressants 453
 alter mesostriatal dopamine interactions with
 serotonin signaling 453
- Antipsychotics 95
 adverse effects of 98
 extrapyramidal effects of 98
 hyperprolactinemia by 99
 pharmacokinetic differences in 96
 sex differences in pharmacokinetics of 95,96
 sexual adverse effects of 99
- Anxiety 333
 limbic system in 336
- Anxiety disorders 408
 cognitive behavior therapy/behavior therapy
 for child/adolescent 408
- Attention-deficit hyperactivity disorder (ADHD) 317
 amphetamines for 323
 assessment of 320
 atomoxetine for 323
 clinical characteristics of 318
 comorbid substance-related disorder (SRD)
 with 325
 differential diagnosis of 320
 drug treatments for 320
 DSM-IV concept of 318
 epidemiology of 318
 etiology of 318
 gender differences of 318
 in adults 317,319
 management of 320
 methylphenidate for 321
 pharmacological treatments for 317
- Atypical antipsychotics 83
 adverse endocrine metabolic effects of 83
 CYP1A2 activities on 83
 effect of local brain P-glycoprotein 83
 pharmacokinetic interactions of 84
- Behavioral activation 267
 forebrain circuitry involved in 267
 nucleus accumbens dopamine in 267
 of nucleus accumbens dopamine 268
 theoretical approaches to 272
- Cancer 3
 efficacy of screening/referral pathway in 7
 impact of treatment on levels of anxiety/
 depression in 4
 impact on psychological function 3

- physiological effects on mood in 4
 prevalence of anxiety/depression in 4
 Childhood onset schizophrenia 463
 brain imaging studies in 466
 candidate genes in 468
 diagnosis of 463
 genetic studies in 468
 neurobiology of 463
 neurocognitive functioning in 465
 pattern of GM loss in 466
 phenomenology of 463
 risk factors in 464
 structural MRI in 466
 treatment for 468
 Clozapine 87
 pharmacokinetic interactions with atypical
 antipsychotics 87
 Comorbid disorders 465
 Comorbid psychiatric disorders 169
 treatment of 169
 Coronary heart disease (CHD) 245
 as consequence of depression 246
 interventions for 246
 screening issues in 248
 Craving 169
 treatment of 169
 Cytochrome P₄₅₀ (CYP) 1A2 77
 effect of dietary constituents 82
 effect of sex-related topics 82
 effect of smoking 81
 effect on psychotropic drug response 79
 genetic polymorphism of 79
 in metabolism of psychotropic drugs 78
 modulation of 81
 pharmacogenetics of 77
 variability in psychotropic drug response 77

 Delusions 473
 assessment strategies for 478
 definitional issues of 477
 in adolescents 473
 in children 473
 in clinical populations 475
 in emotional/conduct disorder 476
 in mood/anxiety disorders 476
 in non clinical individuals 474
 in psychiatric disorders 475
 in schizophrenia 476
 intervention issues to 481
 predictive value of 477
 theoretical considerations for 479
 Delusional depression 235
 clinical characteristics of 236
 epidemiological/sociodemographic data of 236
 family studies of 239
 in elderly 235
 neurobiological correlates in 238
 neuropsychological studies in 238
 suicidal behaviour in 237
 treatment for 240
 Depression 200,226,245,267,371,404
 anergia in 267
 antidepressant treatment for 373
 antipsychotic treatment for 375
 as consequence of CHD 245
 cardiac rehabilitation in 248
 clinical studies of rTMS in 200
 etiological/screening issues of 245
 in clinical practice 200
 in coronary heart disease patients 245
 in psychiatric disorders 200
 in schizophrenia 371
 in somatic illness 226
 interventions for 246
 mood stabilizers for 377
 non-pharmacological treatments for 377
 psychomotor slowing in 267
 screening issues in 248
 Dopamine 103,456
 and antipsychotics 105
 biological implications of 456
 in locus coeruleus modulation 104
 in NAT/ α 2-adrenoceptor-block synergy 106
 DOR knockout mice 32
 compensatory changes in 33

 Effort-related decision making 275
 cortical involvement in 275
 Electroconvulsive therapy (ECT) 39
 Evidence-based psychotherapies 395
 for anxiety disorder in adolescents 416
 for pediatric anxiety 406
 for pediatric bipolar disorder 418
 for pediatric depression 397
 for pediatric mood/anxiety disorders 395

 Fluvoxamine 84

 Generalised anxiety disorder 290

 Hallucinations 473
 assessment strategies for 478
 definitional issues of 477
 in adolescents 473
 in children 473
 in clinical populations 475
 in emotional/conduct disorder 476
 in mood/anxiety disorders 476
 in non clinical individuals 474
 in psychiatric disorders 475
 in schizophrenia 476

- intervention issues to 481
 predictive value of 477
 theoretical considerations for 479
- Interpersonal psychotherapy (IPT-A) 404
- KOR knockout mice 33
 compensatory changes in 33
- Maternal postpartum psychiatric illness 155
- Mesostriatal dopamine system 453
 anatomy of 453
 dopamine receptors in 453
 dopamine transporters in 454
 dopamine/serotonin co-signaling in 456
 in depression 454
- Metacognition 192
 functional implications of deficits of 195
 implications for cognitive remediation 195
- Methamphetamine 381
 comparison in 386
 etiology between psychedelic drug flashbacks
 flashbacks due to 386
 implication in schizophrenia 381
 induced behavioral sensitization 381
 molecular bases of induced behavioral
 sensitization 388
 neurobiological/molecular bases of 381
 spontaneous recurrence of psychosis due to 381
- Mood disorders 423
 automated tools in 424
 automating collection of mood data in 426
 benefits of automating mood charting in 425
 benefits of daily mood charting in 424
 chronorecord in 424
 monitoring of 423
 mood charting technology in 423
 paper-based mood charting of 423
 problems with paper-based mood charting in 424
- MOR knockout mice 29
 actions of classes of abused drugs in 29
 compensatory changes in 31
- Motivational interviewing 207
 effects of 208
 in patients with psychiatric disorders 209
- Multiple opioid receptor gene knockout mice 33
- Neglect syndrome 439
 striatal dopaminergic levels in 445
- Non-literal language processing 311
 cognitive processes likely to be involved in 311
 executive dysfunction hypothesis of 312
- Noradrenergic neurons 103
 cortical dopamine as co-transmitter in 103
 extracellular catecholamine concentrations of 103
- Noradrenergic receptor 104
 mediated effects of 104
- Nucleus accumbens DA 269
 in behavioral economics of effort-related
 decision making 270
 in motivated behavior 269
- Obsessive-compulsive disorder (OCD) 11,290
 deep brain stimulation in 21
 dorsolateral prefrontal cortex-related functions
 in 14
 exposure/response prevention therapy in 20
 functional neurosurgery in 20
 implications for treatment of 11
 implicit/explicit memory in 17
 memory in 16
 neuropsychological consequences of therapeutic
 interventions in 19
 neuropsychological predictors of response to
 therapeutic interventions in 11,18
 non-verbal/verbal memory in 16
 orbitomedial prefrontal cortex-related functions
 in 14
 serotonin reuptake inhibitors in 18
 visuospatial abilities in 18
- Obsessive-compulsive symptoms (OCS) 290
- Oestrogen 339
 advantages/disadvantages of 348
 as protective factor in schizophrenia 339
 biochemical/basic genomic mechanisms of 346
 effects in intervention designs 347
 in antipsychotic treatment 344
 in general medicine 348
 in pre-postpartum psychoses 344
 modulating effects on D2/neurotransmitter
 systems 347
- Olanzapine 87
 pharmacokinetic interactions with atypical
 antipsychotics 87
- Omega-3 fatty acids 215
 in anxiety disorders 226
 in attention-deficit/hyperactivity disorder 227
 in autistic spectrum disorders 228
 in bipolar disorder 222
 in borderline personality disorder 226
 in childhood developmental 226
 in dyslexia 228
 in dyspraxia 228
 in health 217
 in modern diet 217
 in mood disorders 220
 in postpartum depression 225
 in psychiatric disorders 226
 in schizophrenia 218
 in suicidality 226
 in unipolar major depression 223

- metabolism of 215
prevention/treatment of psychiatric disorders
by 215
structure of 215
- Opiate 27
acute actions in MOR knockout mice 27
chronic actions in MOR knockout mice 29
- Opioid receptors 27
role in rewarding effects of several classes of
addictive drugs 27
transgenic mouse studies of 27
- Postartum anxiety disorders 154
- Postpartum blues 152
- Postpartum depression 152
- Postpartum mood disorders 151
etiology of 151
- Postpartum psychiatric disorders 151
cultural considerations of 155
lactation issues to 154
life cycle stage challenges in 156
- Postpartum psychosis 153
- Proton magnetic resonance spectroscopy 39
as monitoring tool for electroconvulsive therapy
effects on brain 39
- Psychiatric screening 3
of cancer patients 3
- Psychiatric disorders 199
deep brain stimulation in 202
developments in brain stimulation in 199
magnetic seizure therapy for 201
treatment of 199
vagal nerve stimulation for 201
- Psychomotor retardation 275
DA systems in 275
frontal/striatal circuits in 275
- Psychosocial psychosis 353
- Psychotic depression 235
clinical characteristics of 236
epidemiological/sociodemographic data of 236
family studies of 239
in elderly 235
neurobiological correlates in 238
neuropsychological studies in 238
suicidal behaviour in 237
treatment for 240
- Psychotropic drugs 95
effects of synthetic hormones in
pharmacokinetics of 96
sex differences in pharmacokinetics of 95
- Psychotic disorders 207,487
behaviour change in patients with 209
intervention for 487
model for 489
- moral position of treatment adherence therapy
in 492
- motivational interviewing in 207
to improve adherence in patients with 488
treatment adherence in patients with 487
- Rapid cycling bipolar disorder 361
anticonvulsants for 362
atypical antipsychotics for 363
combination treatments for 364
treating with novel medications 361
treatment trials with medications 365
- Schizophrenia 95,189,255,309,339,371,431,439
age of onset in 256
attention in 442
by brain abnormalities 259
by brain lateralization 260
characteristics of cognitive impairments in 190
clinical tests of neglect in patients with 440
cognitive dysfunction in 439
cognitive performance in 189,191
conceptual questions regarding 194
course of illness in 256
effect of gender 339
environmental factors for 257
estrogen protection hypothesis for 260
estrogen utilization as treatment in 98
estrogen/psychopathology in 261
for pragmatic deficits in communication
abilities in 309
functional deficits in 189,191
gender differences in 255
genetic liabilities in 257
importance of metacognition in 189
in women 95
line bisection performance in 441
magnocellular hypothesis of 448
mood stabilizers for 377
motor imagery in 442,443
neurochemical effects in 261
neurodevelopmental model for 256
neuroprotective influence in 261
non-literal language deficits in 310
non-literal language processing in 310
non-pharmacological treatments for 377
parietal dysfunction in 448
pathogenic events in 258
real-world functional outcome in 189
sex-based pharmacotherapy in 95
social cognition deficit in 309
state markers in 434
striatal dopaminergic levels in 445
symptom expression in 256
temporal perception in 442,444
theoretical approaches to gender differences in 256
trait vs. state markers for 431
treatment of depressive symptoms in 372
utility of estrogenic treatment in patients with .. 97

- visual motion perception in 434
 visual processes in 431,434
 visuomotor processes in 432
- Schizophrenia spectrum disorders 285
 panic attacks/disorder/agoraphobia in 290
 prevalence of comorbid anxiety disorders in ... 285
 prevalence rates of 286
 social phobia in 295
 temporal relationship with comorbid anxiety disorders 295
- Serotonin 455
 biological implications of 456
 in depression 455
 in mesostriatal system 455
- Serotonin transporter 111
 imaging in neurological disease 125
 imaging in psychiatric disorders 117
 in affective disorders/suicidality 121
 in anxiety disorders 121
 in physiological conditions 114
 in psychiatric disorders 125
 in substance abuse 117
 neuroimaging of 111
 radioligands of imaging in humans 112
- Shared psychotic disorder (SPD) 353
 assessment/differential diagnosis of 355
 biological perspective of 357
 clinical symptomatology of 354
 cognitive perspective of 357
 development of 356
 epidemiology of 355
 prognosis of 358
 psychodynamic perspective of 356
 treatment for 358
- Social cognition 309
- Stress sensitization 382
 in spontaneous recurrence of methamphetamine psychosis 382
- Suicide 51
 adrenergic receptors in 57
 β -adrenergic receptors in 57
 α -adrenergic receptors in 58
 BDNF/TrkB receptors in 66
 biological factors associated with 52
 G proteins in 60
 5HT_{1AS} receptors in 55
 5HT_{2A} receptors in 55
 5HT_{2c} receptors in 56
 in adolescents/teenagers 51
 monoamine receptors in 51
 myristoylated alanine-rich C kinase substrate (MARCKS) in 63
 phosphoinositide/adenylyl cyclase signaling systems in 59
 phospholipase C (PLC) in 61
 PKA in 64
 protein kinase C in 61
 receptor linked signal transduction in 59
 serotonin receptors in 54
 serotonin receptors subtypes in 54,55
 serotonin transporter in 53
 signal transduction mechanisms in 51
 transcription factor CREB in 65
- Tinnitus 333
 limbic system in 336
 link to anxiety 333
 origin of 335
 unified model for 336
- Transcranial magnetic stimulation (TMS) 199
- Visual motion processing 433
 neurophysiology of 433
 genetics of 433